Arqule - Interessantes Nanotechinvestment !! - 500 Beiträge pro Seite
eröffnet am 08.09.03 15:15:49 von
neuester Beitrag 19.12.03 16:22:50 von
neuester Beitrag 19.12.03 16:22:50 von
Beiträge: 18
ID: 773.304
ID: 773.304
Aufrufe heute: 0
Gesamt: 1.636
Gesamt: 1.636
Aktive User: 0
ISIN: US04269E1073 · WKN: 903396
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2202 | +309,05 | |
| 6,7200 | +68,42 | |
| 52,74 | +54,21 | |
| 3,2000 | +52,38 | |
| 1,4500 | +49,94 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8100 | -24,27 | |
| 2,1450 | -25,52 | |
| 5,4000 | -32,16 | |
| 0,9500 | -43,11 | |
| 2,0400 | -58,87 |
Feedback
Hallo Leute
Schaut Euch mal Arqule an. Sieht sehr interessant aus. Vielleicht steht uns da ja eine ähnliche Entwicklung, wie bei NVE und FLML bevor. Die haben ca 90 mio$ Cash in der Kasse. Sind im Depot des Nanotechreports enthalten.
Was sagt Ihr zu der Sache ?
Schaut Euch mal Arqule an. Sieht sehr interessant aus. Vielleicht steht uns da ja eine ähnliche Entwicklung, wie bei NVE und FLML bevor. Die haben ca 90 mio$ Cash in der Kasse. Sind im Depot des Nanotechreports enthalten.
Was sagt Ihr zu der Sache ?
Arqule Completes Acquisition of Cyclis Pharmaceuticals
Monday September 8, 7:01 am ET
Acquisition provides near-term cancer clinical candidate, discovery pipeline and molecular biology expertise
WOBURN, Mass., Sept. 8 /PRNewswire-FirstCall/-- ArQule, Inc. (Nasdaq: ARQL - News), a drug discovery and development company, today announced that it has completed its acquisition of Cyclis Pharmaceuticals, Inc., a privately held cancer-therapeutics company. Cyclis was an Ampersand Ventures portfolio company.
"We are delighted to complete this acquisition," said Dr. Stephen A. Hill, President and CEO of ArQule. "ArQule is now able to combine its strengths in small-molecule chemistry and intelligent drug design with Cyclis` molecular biology expertise. We believe that this combination has the potential to deliver clinical candidates with improved activity and reduced toxicity over other molecular approaches and traditional cancer chemotherapy. We also welcome our Cyclis colleagues, including 13 research scientists, into the ArQule family."
On July 17, 2003, ArQule announced the signing of a definitive agreement to acquire all of Cyclis` outstanding shares on a fully diluted basis in exchange for approximately 4.6 million common shares of ArQule and $5 million in cash. This resulted in a transaction value of approximately $25 million. In addition, ArQule has assumed all of the outstanding debt and liabilities of Cyclis, which range between $5 and $6 million.
"I believe that combining Cyclis` cutting-edge discovery research with ArQule`s proven strength in chemistry can produce a uniquely strong drug development platform," said Dr. Samuel K. Ackerman, Cyclis President and CEO, who will become an advisor to ArQule following the merger.
Portfolio Update
ArQule`s oncology portfolio is based on a novel technology, Activated Checkpoint Therapy(TM) (ACT), which involves the activation of cell cycle checkpoint pathways and the resultant apoptosis, or programmed death, of abnormal cells. ArQule expects its lead cancer compound, CO-501, to enter Phase I clinical trials in 2003. In addition to CO-501, ArQule is pursuing a second-generation program based on a similar mechanism of action for the same pathway. ArQule also is applying ACT to two other discovery programs that target different pathways. The first involves discovering compounds to inhibit a series of proteins referred to as Cancer Survival Proteins or CSPs. CSPs are known to block checkpoint-mediated apoptosis. A second discovery effort is aimed at restoring the p53 pathway to cancer cells through an intracellular protein that has been shown to stimulate cancer cell death.
In addition to cancer therapeutics, ArQule continues to advance its p38 MAP Kinase program for which the initial indication will be rheumatoid arthritis. The Company has a number of compounds in advanced lead optimization that have demonstrated functional oral activity in a rat model of rheumatoid arthritis. In this established animal model, the data indicate that ArQule`s compounds reduced joint swelling in a dose-dependent manner and were well tolerated at all doses studies. ArQule recently commenced pilot- toxicology studies in order to meet its goal of selecting a GLP-toxicology candidate by the end of the year.
In addition to these internal programs, two pharmaceutical partners are conducting GLP-toxicology studies on two ArQule-identified compounds.
Chemical Technologies Update
ArQule continues to meet all of its obligations to pharmaceutical partners. In addition, the Company is pursuing business opportunities based on its chemical technologies platform.
ArQule, Inc., a recognized leader in small-molecule chemistry, is engaged in the discovery and development of novel drugs for the treatment of cancer and inflammatory diseases. ArQule is combining molecular biology expertise and a unique approach to anti-cancer therapies, Activated Checkpoint Therapy(TM) (ACT), with its small molecule chemistry expertise and method for discovering Optimal Chemical Entities(TM) (OCEs(TM)). OCE`s are small-molecule compounds designed for an optimal balance of drug-like properties. ArQule also provides high quality library design and compound production to pharmaceutical collaborators.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in the forward-looking statements or historical performance due to numerous risks and uncertainties that exist in ArQule`s operations, development efforts and the business environment, including without limitation: the acquisition of Cyclis may not create value for ArQule`s shareholders; the ability to successfully integrate acquired technologies and assets; positive early stage preclinical results may not be repeated in later studies or in humans; as a result of unforeseen delays ArQule may not be able to identify a p38 MAP Kinase candidate for GLP- toxicology testing by the end of 2003; other compounds in the series may not demonstrate favorable characteristics; the ability to successfully satisfy milestones and deliver compounds to corporate collaborators; the ability to design OCEs(TM); the progress of product research and development activities in ArQule`s present portfolio and projected expenditures; the ACT approach may not improve efficacy nor reduce toxicity; the therapeutic index for CO-501 may prove narrower than expected giving ArQule less flexibility in selecting doses for the Phase I trial; due to the inability to enter into future collaborations with pharmaceutical or biotechnology companies or raise additional funds in uncertain equity markets, ArQule may not be able to commence clinical trials for CO-501 in 2003 or ever; ArQule`s next-generation programs may fail; ArQule`s chemistry expertise may not contribute to advancing its pipeline; the market opportunity for ArQule`s compounds may disappoint and competition may become more challenging than anticipated; and, the risks and uncertainties described in ArQule`s Form 10-K filed with the Securities and Exchange Commission on March 31, 2003. The forward-looking statements contained herein represent the judgment of ArQule as of the date of this report. ArQule disclaims any intent or obligation to update any forward- looking statement except to the extent required by law.
Monday September 8, 7:01 am ET
Acquisition provides near-term cancer clinical candidate, discovery pipeline and molecular biology expertise
WOBURN, Mass., Sept. 8 /PRNewswire-FirstCall/-- ArQule, Inc. (Nasdaq: ARQL - News), a drug discovery and development company, today announced that it has completed its acquisition of Cyclis Pharmaceuticals, Inc., a privately held cancer-therapeutics company. Cyclis was an Ampersand Ventures portfolio company.
"We are delighted to complete this acquisition," said Dr. Stephen A. Hill, President and CEO of ArQule. "ArQule is now able to combine its strengths in small-molecule chemistry and intelligent drug design with Cyclis` molecular biology expertise. We believe that this combination has the potential to deliver clinical candidates with improved activity and reduced toxicity over other molecular approaches and traditional cancer chemotherapy. We also welcome our Cyclis colleagues, including 13 research scientists, into the ArQule family."
On July 17, 2003, ArQule announced the signing of a definitive agreement to acquire all of Cyclis` outstanding shares on a fully diluted basis in exchange for approximately 4.6 million common shares of ArQule and $5 million in cash. This resulted in a transaction value of approximately $25 million. In addition, ArQule has assumed all of the outstanding debt and liabilities of Cyclis, which range between $5 and $6 million.
"I believe that combining Cyclis` cutting-edge discovery research with ArQule`s proven strength in chemistry can produce a uniquely strong drug development platform," said Dr. Samuel K. Ackerman, Cyclis President and CEO, who will become an advisor to ArQule following the merger.
Portfolio Update
ArQule`s oncology portfolio is based on a novel technology, Activated Checkpoint Therapy(TM) (ACT), which involves the activation of cell cycle checkpoint pathways and the resultant apoptosis, or programmed death, of abnormal cells. ArQule expects its lead cancer compound, CO-501, to enter Phase I clinical trials in 2003. In addition to CO-501, ArQule is pursuing a second-generation program based on a similar mechanism of action for the same pathway. ArQule also is applying ACT to two other discovery programs that target different pathways. The first involves discovering compounds to inhibit a series of proteins referred to as Cancer Survival Proteins or CSPs. CSPs are known to block checkpoint-mediated apoptosis. A second discovery effort is aimed at restoring the p53 pathway to cancer cells through an intracellular protein that has been shown to stimulate cancer cell death.
In addition to cancer therapeutics, ArQule continues to advance its p38 MAP Kinase program for which the initial indication will be rheumatoid arthritis. The Company has a number of compounds in advanced lead optimization that have demonstrated functional oral activity in a rat model of rheumatoid arthritis. In this established animal model, the data indicate that ArQule`s compounds reduced joint swelling in a dose-dependent manner and were well tolerated at all doses studies. ArQule recently commenced pilot- toxicology studies in order to meet its goal of selecting a GLP-toxicology candidate by the end of the year.
In addition to these internal programs, two pharmaceutical partners are conducting GLP-toxicology studies on two ArQule-identified compounds.
Chemical Technologies Update
ArQule continues to meet all of its obligations to pharmaceutical partners. In addition, the Company is pursuing business opportunities based on its chemical technologies platform.
ArQule, Inc., a recognized leader in small-molecule chemistry, is engaged in the discovery and development of novel drugs for the treatment of cancer and inflammatory diseases. ArQule is combining molecular biology expertise and a unique approach to anti-cancer therapies, Activated Checkpoint Therapy(TM) (ACT), with its small molecule chemistry expertise and method for discovering Optimal Chemical Entities(TM) (OCEs(TM)). OCE`s are small-molecule compounds designed for an optimal balance of drug-like properties. ArQule also provides high quality library design and compound production to pharmaceutical collaborators.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in the forward-looking statements or historical performance due to numerous risks and uncertainties that exist in ArQule`s operations, development efforts and the business environment, including without limitation: the acquisition of Cyclis may not create value for ArQule`s shareholders; the ability to successfully integrate acquired technologies and assets; positive early stage preclinical results may not be repeated in later studies or in humans; as a result of unforeseen delays ArQule may not be able to identify a p38 MAP Kinase candidate for GLP- toxicology testing by the end of 2003; other compounds in the series may not demonstrate favorable characteristics; the ability to successfully satisfy milestones and deliver compounds to corporate collaborators; the ability to design OCEs(TM); the progress of product research and development activities in ArQule`s present portfolio and projected expenditures; the ACT approach may not improve efficacy nor reduce toxicity; the therapeutic index for CO-501 may prove narrower than expected giving ArQule less flexibility in selecting doses for the Phase I trial; due to the inability to enter into future collaborations with pharmaceutical or biotechnology companies or raise additional funds in uncertain equity markets, ArQule may not be able to commence clinical trials for CO-501 in 2003 or ever; ArQule`s next-generation programs may fail; ArQule`s chemistry expertise may not contribute to advancing its pipeline; the market opportunity for ArQule`s compounds may disappoint and competition may become more challenging than anticipated; and, the risks and uncertainties described in ArQule`s Form 10-K filed with the Securities and Exchange Commission on March 31, 2003. The forward-looking statements contained herein represent the judgment of ArQule as of the date of this report. ArQule disclaims any intent or obligation to update any forward- looking statement except to the extent required by law.
ArQule, Inc. and Novartis Institutes for BioMedical Research, Inc. Initiate Chemistry Collaboration
Thursday September 4, 7:01 am ET
ArQule to apply lead generation and optimization platform to create novel small-molecule candidates for anti-infective targets
WOBURN, Mass., Sept. 4 /PRNewswire-FirstCall/ -- ArQule, Inc. (Nasdaq: ARQL - News), a drug discovery and development company, today announced that it has entered into a chemistry collaboration with Novartis Institutes for BioMedical Research, Inc. (NIBRI), an affiliate of Novartis AG. As part of this collaboration, ArQule will apply its integrated chemistry technology platform to generate and optimize small-molecule compounds for NIBRI`s anti-infective drug discovery program. The terms of the agreement were not disclosed.
"The addition of Novartis, one of the world`s leading R&D organizations, to our list of partners is further validation of our chemistry technologies business," said Dr. Stephen A. Hill, ArQule`s President and Chief Executive Officer. "This announcement confirms our ability to add new customers for our chemistry services while continuing to build our internal proprietary portfolio of discovery and development programs."
ArQule, Inc., a recognized leader in small-molecule chemistry, is engaged in the discovery and development of novel drugs for the treatment of cancer and inflammatory diseases. Through its acquisition of Cyclis Pharmaceuticals, ArQule intends to combine molecular biology expertise and a unique approach to anti-cancer therapies, Activated Checkpoint Therapy(TM) (ACT), with ArQule`s small-molecule chemistry expertise and method for discovering Optimal Chemical Entities(TM) (OCEs(TM)). OCE`s are small-molecule compounds designed for an optimal balance of drug-like properties. ArQule also provides high quality library design and compound production to pharmaceutical collaborators.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in the forward-looking statements or historical performance due to numerous risks and uncertainties that exist in ArQule`s operations, development efforts and the business environment, including without limitation: ArQule may not be able to apply its technology platform to produce successfully compounds for NIBRI; ArQule may never successfully transform itself into an efficient drug discovery and development company; ArQule may not be able to successfully close the acquisition of Cyclis Pharmaceuticals, Inc., or successfully integrate the acquired technologies and assets; the possibility that anticipated benefits resulting from the acquisition of Cyclis may not be realized; unforeseen circumstances or events relating to the progress of product research and development activities in ArQule`s portfolio and projected expenditures relating thereto; and, the risks and uncertainties described in ArQule`s Form 10-K filed with the Securities and Exchange Commission on March 31, 2003. The forward-looking statements contained herein represent the judgment of ArQule as of the date of this report. ArQule disclaims any intent or obligation to update any forward-looking statement except to the extent required by law.
Thursday September 4, 7:01 am ET
ArQule to apply lead generation and optimization platform to create novel small-molecule candidates for anti-infective targets
WOBURN, Mass., Sept. 4 /PRNewswire-FirstCall/ -- ArQule, Inc. (Nasdaq: ARQL - News), a drug discovery and development company, today announced that it has entered into a chemistry collaboration with Novartis Institutes for BioMedical Research, Inc. (NIBRI), an affiliate of Novartis AG. As part of this collaboration, ArQule will apply its integrated chemistry technology platform to generate and optimize small-molecule compounds for NIBRI`s anti-infective drug discovery program. The terms of the agreement were not disclosed.
"The addition of Novartis, one of the world`s leading R&D organizations, to our list of partners is further validation of our chemistry technologies business," said Dr. Stephen A. Hill, ArQule`s President and Chief Executive Officer. "This announcement confirms our ability to add new customers for our chemistry services while continuing to build our internal proprietary portfolio of discovery and development programs."
ArQule, Inc., a recognized leader in small-molecule chemistry, is engaged in the discovery and development of novel drugs for the treatment of cancer and inflammatory diseases. Through its acquisition of Cyclis Pharmaceuticals, ArQule intends to combine molecular biology expertise and a unique approach to anti-cancer therapies, Activated Checkpoint Therapy(TM) (ACT), with ArQule`s small-molecule chemistry expertise and method for discovering Optimal Chemical Entities(TM) (OCEs(TM)). OCE`s are small-molecule compounds designed for an optimal balance of drug-like properties. ArQule also provides high quality library design and compound production to pharmaceutical collaborators.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in the forward-looking statements or historical performance due to numerous risks and uncertainties that exist in ArQule`s operations, development efforts and the business environment, including without limitation: ArQule may not be able to apply its technology platform to produce successfully compounds for NIBRI; ArQule may never successfully transform itself into an efficient drug discovery and development company; ArQule may not be able to successfully close the acquisition of Cyclis Pharmaceuticals, Inc., or successfully integrate the acquired technologies and assets; the possibility that anticipated benefits resulting from the acquisition of Cyclis may not be realized; unforeseen circumstances or events relating to the progress of product research and development activities in ArQule`s portfolio and projected expenditures relating thereto; and, the risks and uncertainties described in ArQule`s Form 10-K filed with the Securities and Exchange Commission on March 31, 2003. The forward-looking statements contained herein represent the judgment of ArQule as of the date of this report. ArQule disclaims any intent or obligation to update any forward-looking statement except to the extent required by law.
Ich bin auch noch mit ein paar tausend Stücken dabei.
Arqule arbeitet nur mit Toppartnern (u.a. Pfizer)
Ich sehe hier auch ein Riesenpotential in den nächsten 12 Monaten.
Der Kurs dürfte durch die hohe Cashposition nach unten abgesichert sein.
Arqule arbeitet nur mit Toppartnern (u.a. Pfizer)
Ich sehe hier auch ein Riesenpotential in den nächsten 12 Monaten.
Der Kurs dürfte durch die hohe Cashposition nach unten abgesichert sein.
Trading Spotlight
Habe ich bei Nanoinvests gefunden: Chat mit Beckmann
Sehr geehrte Herren,
Sie sprachen in Ihrem letzten Nanotech-Report davon, dass "ArQule" Zusammenarbeiten mit vielen kleinen Nanotechunternehmen eingegangen ist. Hierüber konnte ich bis jetzt nicht finden.
Welche Kooperationen sind das? Und warum ist, in Anbetracht dieses Hintergrundes, Ihrer Meinung nach ArQule ein Wert mit Zukunft?
Mit feundlichen Grüßen
Börsenfalke
Marco Beckmann, Philip Lenz
ArQule halten wir für ein hervorragend aufgestelltes Unternehmen mit einer gewachsenen Kompetenz im Bereich der Auffindung und Entwicklung von therapeutischen Wirkstoffen, den "Small-Molecule-Drugs".
Bereits Anfang 2001 ging das Unternehmen beispielsweise eine Kooperation mit der kanadischen Nanodesign Inc. ein, um eine neue Plattformtechnologie für die Wirkstoffentdeckung zu entwickeln.
Das Unternehmen ist in der Tat ein zukunftsorientierter Wert mit großem Potenzial, über den wir in einer der kommenden Ausgaben des Nanotech-Reports auch eine ausführliche Analyse bringen werden!
Sehr geehrte Herren,
Sie sprachen in Ihrem letzten Nanotech-Report davon, dass "ArQule" Zusammenarbeiten mit vielen kleinen Nanotechunternehmen eingegangen ist. Hierüber konnte ich bis jetzt nicht finden.
Welche Kooperationen sind das? Und warum ist, in Anbetracht dieses Hintergrundes, Ihrer Meinung nach ArQule ein Wert mit Zukunft?
Mit feundlichen Grüßen
Börsenfalke
Marco Beckmann, Philip Lenz
ArQule halten wir für ein hervorragend aufgestelltes Unternehmen mit einer gewachsenen Kompetenz im Bereich der Auffindung und Entwicklung von therapeutischen Wirkstoffen, den "Small-Molecule-Drugs".
Bereits Anfang 2001 ging das Unternehmen beispielsweise eine Kooperation mit der kanadischen Nanodesign Inc. ein, um eine neue Plattformtechnologie für die Wirkstoffentdeckung zu entwickeln.
Das Unternehmen ist in der Tat ein zukunftsorientierter Wert mit großem Potenzial, über den wir in einer der kommenden Ausgaben des Nanotech-Reports auch eine ausführliche Analyse bringen werden!
Moin zusammen,
auch ich bin bereits investiert und kann diesen Wert nur loben. Wer noch zögert sollte sich mal deren Homepage http://www.arqule.com anschauen - da zieht es euch die Socken aus!! Das ist ein erstklassiges Unternehmen... ich bin mir sicher das die verfielfachungspotenzial haben und garantiert nicht mehr lange so günstig zu haben sind!
Gute Arbeit, Nanooo! Über solche Werte sollte hier mehr diskutiert werden!
Isonics
auch ich bin bereits investiert und kann diesen Wert nur loben. Wer noch zögert sollte sich mal deren Homepage http://www.arqule.com anschauen - da zieht es euch die Socken aus!! Das ist ein erstklassiges Unternehmen... ich bin mir sicher das die verfielfachungspotenzial haben und garantiert nicht mehr lange so günstig zu haben sind!
Gute Arbeit, Nanooo! Über solche Werte sollte hier mehr diskutiert werden!
Isonics
Die Firma hat eine Marktkapitalisierung von 100 Mio bei 80 Mio Cash. Das ist fast geschenkt. In der Spitze stand die Aktie bei knapp 40 $, heute nur noch bei 4,7 $.
Die Gewichtung von 6% im DAC Fonds stimmt mich ebenfalls positiv.
Der Beckmann muss für ca. 1 Mio Euro Aktien nachkaufen, wenn er diese Gewichtung bei einem Fondsvolumen von 10 Mio beibehalten möchte, dass wird den Kurs auf jeden Fall nach oben treiben.
Die Gewichtung von 6% im DAC Fonds stimmt mich ebenfalls positiv.
Der Beckmann muss für ca. 1 Mio Euro Aktien nachkaufen, wenn er diese Gewichtung bei einem Fondsvolumen von 10 Mio beibehalten möchte, dass wird den Kurs auf jeden Fall nach oben treiben.
Am 01. September 2003 wurde von der Hauck & Aufhäuser Investment Gesellschaft S.A. der H&A Lux DAC NANOTECH-FONDS gegründet. Eine Vertriebszulassung gem. §15 c Auslandinvestment Gesetz (AuslInvestmG) in Deutschland ist vorgesehen. Aus diesem Anlass finden Sie im vorliegenden „nanotech-special“ ein Interview mit dem Nanotech-Experten, Buchautor und Chefredakteur des Nanotech-Reports Marco Beckmann, erschienen im Börsenmagazin „Der Aktionär“ am 20. August 2003. Nähere Informationen zum H&A Lux DAC NANOTECH-FONDS erhalten Sie unter der kostenlosen Telefonnummer 0800-872 33 24.
Klein, kleiner … nano!
Als die „mit Abstand innovativste und aussichtsreichste Technologie“ revolutioniert die Nanotechnologie täglich die verschiedensten Branchen mit neuartigen Produkten. Im Reich der Zwerge brodelt es zunehmend. Unternehmen, die im Bereich Nanotechnologie tätig sind, rücken immer mehr in den Fokus der Anleger. Marco Beckmann, erfolgreicher Buchautor und Chefredakteur des Nanotech-Report, ist Experte auf dem Gebiet der Nanotechnologie. In einem Gespräch mit dem aktionär erläutert Marco Beckmann das enorme Potenzial sowie die zukünftige Entwicklung dieser noch jungen Technologie.
DER AKTIONÄR: Herr Beckmann, die Nanotechnologie wird als eine der Schlüsseltechnologien des 21. Jahrhunderts bezeichnet. Was verbirgt sich hinter dieser Wissenschaft und welches Potenzial ist sowohl für Unternehmen als auch für Anleger zu erwarten?
Marco Beckmann: Bei der Nanotechnologie handelt es sich um die gezielte Konstruktion in atomaren und molekularen Dimensionen. Vereinfacht gesagt „bastelt“ man nach dem Lego-Prinzip mit nanometergroßen Bausteinen an neuen Materialien oder konstruiert molekulare Motoren und Computerbauteile aus einzelnen Atomen. Per Definition werden Systeme mit einer Maximalgröße von weniger als hundert Nanometern der Nanotechnologie zugeordnet. Ein Nanometer stellt den milliardsten Bruchteil eines Meters dar, auf dieser Länge lassen sich ungefähr fünf bis zehn einzelne Atome nebeneinander unterbringen. Das Potenzial der Nanotechnologie für Unternehmen und Anleger ist größer als das jeder bisher bekannten technologischen Entwicklung: Experten bezeichnen die Nanotechnologie schon als möglichen Auslöser einer neuen industriellen Revolution.
DER AKTIONÄR: Noch vor einem Jahr war die Nanotechnologie ein Thema, das weitgehend unbekannt war. Doch die Kursentwicklung vieler Nano-Aktien zeigt, dass die Anleger das riesige Potenzial erkannt haben. Wie schätzen Sie die zukünftige Entwicklung ein?
Marco Beckmann: Trotz der positiven Entwicklung vieler Nano-Stocks in den vergangenen Monaten müssen wir uns darüber im Klaren sein, dass wir immer noch am Anfang stehen. Mit der Nanotechnologie entfaltet sich die mit Abstand innovativste und aussichtsreichste Technologie, mit der sich die Gesellschaft, Forschung und Investmentszene gegenwärtig auseinandersetzt. Die Auswirkungen dieser Technologie auch für die Finanzmärkte sind derart fundamental, dass man ohne Übertreibung von einer der größten Chancen für Anleger überhaupt sprechen kann. Vor diesem Hintergrund ist in den kommenden Monaten und Jahren mit deutlichen Wachstumsschüben bei innovativen Nanotechnologie-Unternehmen zu rechnen.
DER AKTIONÄR: Besonders in den USA zeichnet sich momentan der Trend ab, die Vorsilbe „nano“ im Unternehmensnamen zu führen. Einige schwarze Schafe werden somit auch versuchen von dem riesigen Potenzial, das die Nanotechnologie birgt, zu profitieren. Worauf sollten Anleger bei der Auswahl geeigneter Nano-Unternehmen achten?
Marco Beckmann: Jeder Investition in Nanotechnologie-Aktien sollte eine ausführliche Informationsphase über das jeweilige Unternehmen vorangehen. Nur wenn man sich mit der Situation des Unternehmens vertraut macht und das Risiko abschätzen kann, ist man auch bereit, eine längerfristige und gewinnbringende Investition einzugehen. Wer die „Microsoft“ der Zukunft finden will, muss versuchen, die Märkte und die dort möglichen Potenziale realistisch einzuschätzen. Gerade die Vergangenheit hat uns gezeigt, dass man die beste Rendite mit Unternehmen erzielt, die neben einem überdurchschnittlichen Wachstum über saubere Bilanzen und ein erfahrenes Management verfügen.
DER AKTIONÄR: Weltweit stehen Hunderte von aussichtsreichen Nanotechnologie-Unternehmen kurz vor dem Börsengang. Wann wird es Ihrer Meinung nach so weit sein?
Marco Beckmann: Gegenwärtig ist davon auszugehen, dass wir die ersten jungen Nanotech-Unternehmen frühestens im zweiten Halbjahr 2004 an der Börse sehen werden. Viele der Unternehmen sind prinzipiell startklar und warten nur noch darauf, dass sich die Stimmung an den Finanzmärkte nachhaltig aufhellt, um einen möglichst erfolgreichen Börsengang zu erzielen. Doch auch bereits über 150 börsennotierte Unternehmen mit nanotechnologischem Engagement bieten Anlegern schon jetzt die Möglichkeit direkt an der aussichtsreichen Entwicklung der Nanotechnologie teilzuhaben.
DER AKTIONÄR: Sie haben mit „Profitieren von Nanotechnologie. Investment der Zukunft“ das erfolgreichste deutschsprachige Fachbuch zu diesem Thema veröffentlicht. Worauf darf der Leser gespannt sein?
Marco Beckmann: Ziel von „Profitieren von Nanotechnologie“ ist es den zukunftsorientierten Anleger an die Chancen und Möglichkeiten dieser neuen Technologie heranzuführen und ihm das Potenzial in den unterschiedlichen Anwendungsgebieten zu verdeutlichen. Nachdem in der ersten Hälfte des Buches die Nanotechnologie und ihre Einsatzmöglichkeiten erklärt werden, geht es im zweiten Teil um das Thema „Investieren in Nanotechnologie“. Hier werden unter anderem rund 35 teils börsennotierte Unternehmen aus den USA, Japan und Deutschland mit Basisdaten, ihren Entwicklungsstrategien und bereits greifbaren Erfolgen präsentiert. Ein umfangreiches Glossar hilft Anlegern auch nach der Lektüre, den fachlichen Herausforderungen dieser neuen Investitionschance gewachsen zu sein
Klein, kleiner … nano!
Als die „mit Abstand innovativste und aussichtsreichste Technologie“ revolutioniert die Nanotechnologie täglich die verschiedensten Branchen mit neuartigen Produkten. Im Reich der Zwerge brodelt es zunehmend. Unternehmen, die im Bereich Nanotechnologie tätig sind, rücken immer mehr in den Fokus der Anleger. Marco Beckmann, erfolgreicher Buchautor und Chefredakteur des Nanotech-Report, ist Experte auf dem Gebiet der Nanotechnologie. In einem Gespräch mit dem aktionär erläutert Marco Beckmann das enorme Potenzial sowie die zukünftige Entwicklung dieser noch jungen Technologie.
DER AKTIONÄR: Herr Beckmann, die Nanotechnologie wird als eine der Schlüsseltechnologien des 21. Jahrhunderts bezeichnet. Was verbirgt sich hinter dieser Wissenschaft und welches Potenzial ist sowohl für Unternehmen als auch für Anleger zu erwarten?
Marco Beckmann: Bei der Nanotechnologie handelt es sich um die gezielte Konstruktion in atomaren und molekularen Dimensionen. Vereinfacht gesagt „bastelt“ man nach dem Lego-Prinzip mit nanometergroßen Bausteinen an neuen Materialien oder konstruiert molekulare Motoren und Computerbauteile aus einzelnen Atomen. Per Definition werden Systeme mit einer Maximalgröße von weniger als hundert Nanometern der Nanotechnologie zugeordnet. Ein Nanometer stellt den milliardsten Bruchteil eines Meters dar, auf dieser Länge lassen sich ungefähr fünf bis zehn einzelne Atome nebeneinander unterbringen. Das Potenzial der Nanotechnologie für Unternehmen und Anleger ist größer als das jeder bisher bekannten technologischen Entwicklung: Experten bezeichnen die Nanotechnologie schon als möglichen Auslöser einer neuen industriellen Revolution.
DER AKTIONÄR: Noch vor einem Jahr war die Nanotechnologie ein Thema, das weitgehend unbekannt war. Doch die Kursentwicklung vieler Nano-Aktien zeigt, dass die Anleger das riesige Potenzial erkannt haben. Wie schätzen Sie die zukünftige Entwicklung ein?
Marco Beckmann: Trotz der positiven Entwicklung vieler Nano-Stocks in den vergangenen Monaten müssen wir uns darüber im Klaren sein, dass wir immer noch am Anfang stehen. Mit der Nanotechnologie entfaltet sich die mit Abstand innovativste und aussichtsreichste Technologie, mit der sich die Gesellschaft, Forschung und Investmentszene gegenwärtig auseinandersetzt. Die Auswirkungen dieser Technologie auch für die Finanzmärkte sind derart fundamental, dass man ohne Übertreibung von einer der größten Chancen für Anleger überhaupt sprechen kann. Vor diesem Hintergrund ist in den kommenden Monaten und Jahren mit deutlichen Wachstumsschüben bei innovativen Nanotechnologie-Unternehmen zu rechnen.
DER AKTIONÄR: Besonders in den USA zeichnet sich momentan der Trend ab, die Vorsilbe „nano“ im Unternehmensnamen zu führen. Einige schwarze Schafe werden somit auch versuchen von dem riesigen Potenzial, das die Nanotechnologie birgt, zu profitieren. Worauf sollten Anleger bei der Auswahl geeigneter Nano-Unternehmen achten?
Marco Beckmann: Jeder Investition in Nanotechnologie-Aktien sollte eine ausführliche Informationsphase über das jeweilige Unternehmen vorangehen. Nur wenn man sich mit der Situation des Unternehmens vertraut macht und das Risiko abschätzen kann, ist man auch bereit, eine längerfristige und gewinnbringende Investition einzugehen. Wer die „Microsoft“ der Zukunft finden will, muss versuchen, die Märkte und die dort möglichen Potenziale realistisch einzuschätzen. Gerade die Vergangenheit hat uns gezeigt, dass man die beste Rendite mit Unternehmen erzielt, die neben einem überdurchschnittlichen Wachstum über saubere Bilanzen und ein erfahrenes Management verfügen.
DER AKTIONÄR: Weltweit stehen Hunderte von aussichtsreichen Nanotechnologie-Unternehmen kurz vor dem Börsengang. Wann wird es Ihrer Meinung nach so weit sein?
Marco Beckmann: Gegenwärtig ist davon auszugehen, dass wir die ersten jungen Nanotech-Unternehmen frühestens im zweiten Halbjahr 2004 an der Börse sehen werden. Viele der Unternehmen sind prinzipiell startklar und warten nur noch darauf, dass sich die Stimmung an den Finanzmärkte nachhaltig aufhellt, um einen möglichst erfolgreichen Börsengang zu erzielen. Doch auch bereits über 150 börsennotierte Unternehmen mit nanotechnologischem Engagement bieten Anlegern schon jetzt die Möglichkeit direkt an der aussichtsreichen Entwicklung der Nanotechnologie teilzuhaben.
DER AKTIONÄR: Sie haben mit „Profitieren von Nanotechnologie. Investment der Zukunft“ das erfolgreichste deutschsprachige Fachbuch zu diesem Thema veröffentlicht. Worauf darf der Leser gespannt sein?
Marco Beckmann: Ziel von „Profitieren von Nanotechnologie“ ist es den zukunftsorientierten Anleger an die Chancen und Möglichkeiten dieser neuen Technologie heranzuführen und ihm das Potenzial in den unterschiedlichen Anwendungsgebieten zu verdeutlichen. Nachdem in der ersten Hälfte des Buches die Nanotechnologie und ihre Einsatzmöglichkeiten erklärt werden, geht es im zweiten Teil um das Thema „Investieren in Nanotechnologie“. Hier werden unter anderem rund 35 teils börsennotierte Unternehmen aus den USA, Japan und Deutschland mit Basisdaten, ihren Entwicklungsstrategien und bereits greifbaren Erfolgen präsentiert. Ein umfangreiches Glossar hilft Anlegern auch nach der Lektüre, den fachlichen Herausforderungen dieser neuen Investitionschance gewachsen zu sein
ACHTUNG !
Heute findet die UBS konferenz statt .
Gruesse nanooo
Heute findet die UBS konferenz statt .
Gruesse nanooo
Arql ist heute relativ stark !
Gruende ?
Was fuer news gibt es in Bezug UBS Presentation ?
Gruende ?
Was fuer news gibt es in Bezug UBS Presentation ?
Welcome [Sign In] To track stocks & more, Register
Financial News
Enter symbol(s) BasicDayWatchPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup
Press Release Source: ArQule, Inc.
ArQule Initiates First Human Clinical Trial With CO-501
Tuesday September 30, 7:01 am ET
WOBURN, Mass., Sept. 30 /PRNewswire-FirstCall/ -- ArQule, Inc. (Nasdaq: ARQL - News), a drug discovery and development company, today announced that it has initiated the first human clinical trial with CO-501, a novel investigational small-molecule anti-cancer drug. CO-501 is intended to selectively kill cancer cells and spare normal cells by restoring and activating cellular checkpoints known to be defective in cancer.
"Yesterday we dosed our first patient. This is a great beginning for ArQule`s oncology portfolio and hopefully for patients with cancer," said Dr. Stephen A. Hill, President and CEO of ArQule. "The science underlying CO-501 offers great promise for a new generation of safe and effective drugs to treat a broad spectrum of cancers. We believe that this technology, combined with ArQule`s strengths in small-molecule chemistry and intelligent drug design, will enable ArQule to realize its goal of becoming a leading oncology company."
ArQule`s CO-501 is the first clinical-stage compound derived from the Company`s unique biology platform, Activated Checkpoint Therapy(TM) (ACT). CO-501 has the potential for improved activity and reduced toxicity over other molecular approaches and traditional cancer chemotherapy. In preclinical studies, CO-501 showed that it activates the E2F-mediated checkpoints, leading to selective apoptosis of cancer cells. The compound also has demonstrated wide-spectrum anti-cancer activity in mice.
The first Phase I clinical trial for CO-501, a dose-escalation safety study, will evaluate the pharmacokinetic and pharmacodynamic properties of CO-501 in patients with advanced solid tumors. Designed as an open-label, single-arm, non-randomized study, the trial will be conducted at the Dana-Farber/Harvard Cancer Center in three Boston hospitals: Dana-Farber Cancer Institute, Massachusetts General Hospital and Beth Israel Deaconess Medical Center. The trial is expected to enroll between 20 and 40 patients. The principal endpoints are safety, clinical tolerability and determination of recommended Phase II dose.
Dr. Andrew Uprichard, Chief Operating Officer responsible for ArQule`s therapeutic programs, added, "It is exciting to announce the initiation of our first clinical trial, representing as it does the planned growth of ArQule into a drug discovery and development organization. We hope the results of this and subsequent human trials lead to the development of anti-cancer agents with less toxicity than conventional approaches."
In addition to CO-501, ArQule is pursuing second-generation programs based on the E2F checkpoint-apoptosis pathway. ArQule also is pursuing ACT in other internal discovery programs. The first involves discovering compounds to inhibit a series of proteins referred to as Cancer Survival Proteins or CSPs. CSPs block checkpoint-mediated apoptosis. Another discovery program is aimed at restoring the p53 pathway to cancer cells using small-molecule drugs. ArQule also is advancing a program in inflammation for its p38 MAP Kinase inhibitors for which the first indication is intended to be rheumatoid arthritis. ArQule expects to nominate a GLP-toxicology candidate in this program for preclinical testing by the end of 2003.
ArQule, Inc. is engaged in the discovery and development of novel drugs for the treatment of cancer and inflammation. The Company is combining molecular biology expertise and a unique approach to anti-cancer therapies, Activated Checkpoint Therapy(TM) (ACT), with its small-molecule chemistry expertise and method for discovering Optimal Chemical Entities(TM) (OCEs(TM)). OCEs(TM) are small-molecule compounds designed for an optimal balance of drug-like properties. In addition to advancing its own programs, ArQule continues to advance drug discovery efforts of pharmaceutical collaborators by providing high-quality library design and compound production.
Financial News
Enter symbol(s) BasicDayWatchPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup
Press Release Source: ArQule, Inc.
ArQule Initiates First Human Clinical Trial With CO-501
Tuesday September 30, 7:01 am ET
WOBURN, Mass., Sept. 30 /PRNewswire-FirstCall/ -- ArQule, Inc. (Nasdaq: ARQL - News), a drug discovery and development company, today announced that it has initiated the first human clinical trial with CO-501, a novel investigational small-molecule anti-cancer drug. CO-501 is intended to selectively kill cancer cells and spare normal cells by restoring and activating cellular checkpoints known to be defective in cancer.
"Yesterday we dosed our first patient. This is a great beginning for ArQule`s oncology portfolio and hopefully for patients with cancer," said Dr. Stephen A. Hill, President and CEO of ArQule. "The science underlying CO-501 offers great promise for a new generation of safe and effective drugs to treat a broad spectrum of cancers. We believe that this technology, combined with ArQule`s strengths in small-molecule chemistry and intelligent drug design, will enable ArQule to realize its goal of becoming a leading oncology company."
ArQule`s CO-501 is the first clinical-stage compound derived from the Company`s unique biology platform, Activated Checkpoint Therapy(TM) (ACT). CO-501 has the potential for improved activity and reduced toxicity over other molecular approaches and traditional cancer chemotherapy. In preclinical studies, CO-501 showed that it activates the E2F-mediated checkpoints, leading to selective apoptosis of cancer cells. The compound also has demonstrated wide-spectrum anti-cancer activity in mice.
The first Phase I clinical trial for CO-501, a dose-escalation safety study, will evaluate the pharmacokinetic and pharmacodynamic properties of CO-501 in patients with advanced solid tumors. Designed as an open-label, single-arm, non-randomized study, the trial will be conducted at the Dana-Farber/Harvard Cancer Center in three Boston hospitals: Dana-Farber Cancer Institute, Massachusetts General Hospital and Beth Israel Deaconess Medical Center. The trial is expected to enroll between 20 and 40 patients. The principal endpoints are safety, clinical tolerability and determination of recommended Phase II dose.
Dr. Andrew Uprichard, Chief Operating Officer responsible for ArQule`s therapeutic programs, added, "It is exciting to announce the initiation of our first clinical trial, representing as it does the planned growth of ArQule into a drug discovery and development organization. We hope the results of this and subsequent human trials lead to the development of anti-cancer agents with less toxicity than conventional approaches."
In addition to CO-501, ArQule is pursuing second-generation programs based on the E2F checkpoint-apoptosis pathway. ArQule also is pursuing ACT in other internal discovery programs. The first involves discovering compounds to inhibit a series of proteins referred to as Cancer Survival Proteins or CSPs. CSPs block checkpoint-mediated apoptosis. Another discovery program is aimed at restoring the p53 pathway to cancer cells using small-molecule drugs. ArQule also is advancing a program in inflammation for its p38 MAP Kinase inhibitors for which the first indication is intended to be rheumatoid arthritis. ArQule expects to nominate a GLP-toxicology candidate in this program for preclinical testing by the end of 2003.
ArQule, Inc. is engaged in the discovery and development of novel drugs for the treatment of cancer and inflammation. The Company is combining molecular biology expertise and a unique approach to anti-cancer therapies, Activated Checkpoint Therapy(TM) (ACT), with its small-molecule chemistry expertise and method for discovering Optimal Chemical Entities(TM) (OCEs(TM)). OCEs(TM) are small-molecule compounds designed for an optimal balance of drug-like properties. In addition to advancing its own programs, ArQule continues to advance drug discovery efforts of pharmaceutical collaborators by providing high-quality library design and compound production.
Arqlue entwickelt sich in den letzten Tagen nach bisher eher zurückhaltendem Kursverlauf steil nach oben! Hab ich da irgendwelche positive Meldungen versäumt?
Hat jemand Informationen über den plötzlichen Höhenflug?
Hat jemand Informationen über den plötzlichen Höhenflug?
Hier die neuen Zahlen:
Conference call and Webcast scheduled for today at 9 a.m. Eastern Time
WOBURN, Mass., Oct. 23 /PRNewswire-FirstCall/ -- ArQule, Inc. (Nasdaq: ARQL), a drug discovery and development company, today reported its results for the third quarter ended September 30, 2003.
For the third quarter of 2003, ArQule reported revenues of $15,961,000, compared with $16,459,000 for the same period of 2002. For the quarter, the Company reported a net loss of $29,909,000, or $1.22 per share, compared with a net loss of $5,468,000, or $0.26 per share, for the third quarter of 2002. The third-quarter 2003 net loss figure includes an in-process research and development charge related to the acquisition of Cyclis Pharmaceuticals of $30,359,000.
For the nine months ended September 30, 2003, revenues were $47,096,000, compared with revenues of $46,658,000 for the first nine months of 2002. ArQule reported a net loss of $29,622,000, or $1.28 per share, for the first nine months of 2003, compared with a net loss of $18,770,000, or $0.89 per share, for the first nine months of 2002. The nine-month 2003 net loss figure includes the above-mentioned in-process research and development charge.
ArQule ended the third quarter of 2003 with $74 million in cash and marketable securities.
"Our third quarter marked another period of strong achievement for ArQule. Through the dedication and focus of our employees, we furthered ArQule`s strategy of becoming a drug discovery and development organization with a therapeutic focus in oncology. We advanced our pipeline programs, closed our strategic acquisition of Cyclis Pharmaceuticals, began to integrate a novel biology approach to cancer treatment with our unique small-molecule chemistry expertise, and met all collaborator expectations," said Dr. Stephen A. Hill, ArQule`s President and Chief Executive Officer.
Highlights of the Third Quarter
-- A Phase I clinical trial of ArQule`s lead anti-cancer compound, ARQ 501
(formerly CO-501), began in late September.
-- ArQule complemented its strengths in small-molecule chemistry through
the acquisition of Cyclis Pharmaceuticals. As a result, ArQule gained a
novel anti-cancer biology approach, Activated Checkpoint Therapy(SM)
(ACT(SM)); a lead clinical candidate, ARQ 501; a portfolio of cancer
programs based on ACT(SM); and, biology expertise.
-- ArQule named Dr. Chiang J. Li Chief Scientific Officer and Vice
President, Head of ArQule Biomedical Institute. Dr. Li, the co-
inventor of Activated Checkpoint Therapy(SM), is responsible for
ArQule`s discovery research, including target identification and target
validation activities.
-- In its p38 MAP Kinase program for inflammation, ArQule advanced one
compound, an Optimal Chemical Entity(TM) (OCE(TM)) named ARQ 101, into
pilot toxicity studies, comprising acute toxicity, dose-range finding
toxicity, genotoxicity and pharmacokinetics. Based on results from
these studies, ARQ 101 has been nominated as ArQule`s first wholly
owned GLP toxicity candidate. ArQule plans to commence GLP-tox studies
by the end of this year.
-- ArQule fulfilled all requirements of its Pfizer and Bayer agreements
and initiated a new pharmaceutical collaboration with Novartis
Biomedical Research Institute.
Financial Guidance
ArQule is updating financial guidance for the year ending December 31, 2003. ArQule now expects revenues to range between $58 and $60 million. This increase from prior guidance of $56 to $58 million primarily reflects achievements at the high end of expectations for Pfizer.
The Company expects: the total cost of revenue to range between $37 and $38 million; total research and development expense to range between $20 and $21 million; marketing, general and administrative expense to range between $10 and $11 million; and, net investment income to range between $500,000 and $600,000. All these figures are unchanged from second quarter guidance.
ArQule now expects its net loss for 2003 to range from $37 to $39 million, a reduction from previous guidance of $40 to $42 million. This includes the impact of the in-process research and development charge of approximately $30 million related to the close of the Cyclis acquisition.
ArQule now expects its net use of cash to range between $22 and $24 million, a reduction from previous guidance of $24 to $26 million. This includes payments of substantially all of Cyclis` liabilities of approximately $5 million and the cash portion of the purchase price and closing-related costs of $7 million.
ArQule will hold a conference call today at 9:00 a.m. Eastern Time. Dr. Stephen A. Hill, President and Chief Executive Officer, will lead the call and be joined by Dr. Andrew Uprichard, Chief Operating Officer, and Dr. Chiang J. Li, Chief Scientific Officer.
Date: Thursday, October 23, 2003
Time: 9:00 a.m. ET
Conference Call Numbers
Toll Free: (800) 268-8047
Toll: (312) 461-0644
Access Number: 5907532
Webcast: www.ArQule.com
Gruß
Falke28
Conference call and Webcast scheduled for today at 9 a.m. Eastern Time
WOBURN, Mass., Oct. 23 /PRNewswire-FirstCall/ -- ArQule, Inc. (Nasdaq: ARQL), a drug discovery and development company, today reported its results for the third quarter ended September 30, 2003.
For the third quarter of 2003, ArQule reported revenues of $15,961,000, compared with $16,459,000 for the same period of 2002. For the quarter, the Company reported a net loss of $29,909,000, or $1.22 per share, compared with a net loss of $5,468,000, or $0.26 per share, for the third quarter of 2002. The third-quarter 2003 net loss figure includes an in-process research and development charge related to the acquisition of Cyclis Pharmaceuticals of $30,359,000.
For the nine months ended September 30, 2003, revenues were $47,096,000, compared with revenues of $46,658,000 for the first nine months of 2002. ArQule reported a net loss of $29,622,000, or $1.28 per share, for the first nine months of 2003, compared with a net loss of $18,770,000, or $0.89 per share, for the first nine months of 2002. The nine-month 2003 net loss figure includes the above-mentioned in-process research and development charge.
ArQule ended the third quarter of 2003 with $74 million in cash and marketable securities.
"Our third quarter marked another period of strong achievement for ArQule. Through the dedication and focus of our employees, we furthered ArQule`s strategy of becoming a drug discovery and development organization with a therapeutic focus in oncology. We advanced our pipeline programs, closed our strategic acquisition of Cyclis Pharmaceuticals, began to integrate a novel biology approach to cancer treatment with our unique small-molecule chemistry expertise, and met all collaborator expectations," said Dr. Stephen A. Hill, ArQule`s President and Chief Executive Officer.
Highlights of the Third Quarter
-- A Phase I clinical trial of ArQule`s lead anti-cancer compound, ARQ 501
(formerly CO-501), began in late September.
-- ArQule complemented its strengths in small-molecule chemistry through
the acquisition of Cyclis Pharmaceuticals. As a result, ArQule gained a
novel anti-cancer biology approach, Activated Checkpoint Therapy(SM)
(ACT(SM)); a lead clinical candidate, ARQ 501; a portfolio of cancer
programs based on ACT(SM); and, biology expertise.
-- ArQule named Dr. Chiang J. Li Chief Scientific Officer and Vice
President, Head of ArQule Biomedical Institute. Dr. Li, the co-
inventor of Activated Checkpoint Therapy(SM), is responsible for
ArQule`s discovery research, including target identification and target
validation activities.
-- In its p38 MAP Kinase program for inflammation, ArQule advanced one
compound, an Optimal Chemical Entity(TM) (OCE(TM)) named ARQ 101, into
pilot toxicity studies, comprising acute toxicity, dose-range finding
toxicity, genotoxicity and pharmacokinetics. Based on results from
these studies, ARQ 101 has been nominated as ArQule`s first wholly
owned GLP toxicity candidate. ArQule plans to commence GLP-tox studies
by the end of this year.
-- ArQule fulfilled all requirements of its Pfizer and Bayer agreements
and initiated a new pharmaceutical collaboration with Novartis
Biomedical Research Institute.
Financial Guidance
ArQule is updating financial guidance for the year ending December 31, 2003. ArQule now expects revenues to range between $58 and $60 million. This increase from prior guidance of $56 to $58 million primarily reflects achievements at the high end of expectations for Pfizer.
The Company expects: the total cost of revenue to range between $37 and $38 million; total research and development expense to range between $20 and $21 million; marketing, general and administrative expense to range between $10 and $11 million; and, net investment income to range between $500,000 and $600,000. All these figures are unchanged from second quarter guidance.
ArQule now expects its net loss for 2003 to range from $37 to $39 million, a reduction from previous guidance of $40 to $42 million. This includes the impact of the in-process research and development charge of approximately $30 million related to the close of the Cyclis acquisition.
ArQule now expects its net use of cash to range between $22 and $24 million, a reduction from previous guidance of $24 to $26 million. This includes payments of substantially all of Cyclis` liabilities of approximately $5 million and the cash portion of the purchase price and closing-related costs of $7 million.
ArQule will hold a conference call today at 9:00 a.m. Eastern Time. Dr. Stephen A. Hill, President and Chief Executive Officer, will lead the call and be joined by Dr. Andrew Uprichard, Chief Operating Officer, and Dr. Chiang J. Li, Chief Scientific Officer.
Date: Thursday, October 23, 2003
Time: 9:00 a.m. ET
Conference Call Numbers
Toll Free: (800) 268-8047
Toll: (312) 461-0644
Access Number: 5907532
Webcast: www.ArQule.com
Gruß
Falke28
Endlich geht es wieder aufwärts. Die Zahlen waren super - scheinbar haben es einige gestern nicht richtig verstanden.
Ich habe mir gestern nochmal 2500 Stücke dazugelegt.
Im letzten Quartal werden wir wieder Gewinne sehen.
Ich habe mir gestern nochmal 2500 Stücke dazugelegt.
Im letzten Quartal werden wir wieder Gewinne sehen.
Lange nichts mehr von dem wert gelesen, gibt es Neuigkeiten?
War doch mal eine Top Position im Beckmann Fonds.
Knapp 70 Mio Cash bei 90 Mio Marktkapitalisierung!!!
War doch mal eine Top Position im Beckmann Fonds.
Knapp 70 Mio Cash bei 90 Mio Marktkapitalisierung!!!
Das war die letzte Meldung vom 20.11.03
ArQule Cancer Research Makes Top Ten List In Peer-Reviewed Cell Cycle Journal
WOBURN, Mass., Nov. 20 /PRNewswire-FirstCall/ -- ArQule, Inc. (Nasdaq: ARQL), an oncology-focused biotechnology company, reported today that the editorial board of the journal Cell Cycle has selected the Company`s published research on the topic of direct checkpoint activation as a strategy against cancer as one of the "Top Ten Most Outstanding Cell Cycle Research Papers" of the past year published in all biomedical journals. The study, led by ArQule`s Chief Scientific Officer Dr. Chiang J. Li, entitled Selective killing of cancer cells by beta lapachone: Direct checkpoint activation as a strategy against cancer, first appeared in PNAS (Proceedings of the National Academy of Sciences of the USA) in March 2003. Cell Cycle is a peer-reviewed journal of original research on the cell cycle, especially as it pertains to cancer and developmental biology. Its distinguished editorial board consists of academic leaders, including Nobel Laureates, in cell cycle and cancer research.
"This is strong recognition and endorsement by the scientific community of our innovative Activated Checkpoint Therapy(SM) (ACT(SM)) platform, ArQule`s novel approach to anti-cancer therapy," said Dr. Stephen A. Hill, President and Chief Executive Officer. "The ACT(SM) platform underscores ArQule`s oncology portfolio which presently consists of a Phase 1 clinical candidate (ARQ 501) and several discovery programs."
Dr. Chiang J. Li, inventor of the ACT(SM) platform and senior author of the study, added, "My colleagues and I are honored by this peer recognition of our science. We are working to improve the way cancer patients are treated."
The November/December 2003 issue of Cell Cycle acknowledges the most outstanding cell cycle research of the past year with its selection of the top ten papers, chosen from among 40 papers published in all journals between 2002 and mid-2003. The papers were nominated and selected by members of the Cell Cycle Editorial Board who used the following criteria: will the paper affect future basic research or research in therapy or does it describe a new technology?
ArQule, Inc. is a biotechnology company engaged in the research and development of novel small-molecule drugs for the treatment of cancer and inflammation. The Company is applying its innovative Activated Checkpoint Therapy(SM) (ACT(SM)) platform and its small-molecule chemistry expertise to produce next-generation drugs that are aimed at improving the treatment of cancer patients. ACT(SM) platform compounds are intended to selectively kill cancer cells and spare normal cells by restoring and activating cellular checkpoints that are defective in cancer.
ArQule`s leading programs are ARQ 501 for solid cancers, which entered Phase 1 trials in September 2003, and ARQ 101, an OCE(TM) compound targeting p38 MAP Kinase for rheumatoid arthritis, which entered preclinical testing (GLP-toxicity studies) in November.
For more information about Cell Cycle and the current issue, please visit: www.landesbioscience.com/journals/cc/.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in the forward-looking statements or historical performance due to numerous risks and uncertainties that exist in ArQule`s operations, development efforts and the business environment, including without limitation: the ability to integrate successfully ArQule`s biology experience and the ACT(SM) platform with its small-molecule chemistry expertise; the ability to improve the treatment of cancer patients; the ACT(SM) platform may not improve efficacy or reduce toxicity and compounds resulting from the platform may not operate as intended; and, the risks and uncertainties described in ArQule`s Form 10-K filed with the Securities and Exchange Commission on March 31, 2003 and its Form S-3 filed with the Commission on October 8, 2003. The forward-looking statements contained herein represent the judgment of ArQule as of the date of this report. ArQule disclaims any intent or obligation to update any forward-looking statement except to the extent required by law.
SOURCE ArQule, Inc. -0- 11/20/2003 /CONTACT: Stephen A. Hill, CEO, or Jean M. Devine, Director of IR, both of ArQule, Inc., +1-781-994-0300/ /Web site: http://www.arqule.com/ (ARQL)
ArQule Cancer Research Makes Top Ten List In Peer-Reviewed Cell Cycle Journal
WOBURN, Mass., Nov. 20 /PRNewswire-FirstCall/ -- ArQule, Inc. (Nasdaq: ARQL), an oncology-focused biotechnology company, reported today that the editorial board of the journal Cell Cycle has selected the Company`s published research on the topic of direct checkpoint activation as a strategy against cancer as one of the "Top Ten Most Outstanding Cell Cycle Research Papers" of the past year published in all biomedical journals. The study, led by ArQule`s Chief Scientific Officer Dr. Chiang J. Li, entitled Selective killing of cancer cells by beta lapachone: Direct checkpoint activation as a strategy against cancer, first appeared in PNAS (Proceedings of the National Academy of Sciences of the USA) in March 2003. Cell Cycle is a peer-reviewed journal of original research on the cell cycle, especially as it pertains to cancer and developmental biology. Its distinguished editorial board consists of academic leaders, including Nobel Laureates, in cell cycle and cancer research.
"This is strong recognition and endorsement by the scientific community of our innovative Activated Checkpoint Therapy(SM) (ACT(SM)) platform, ArQule`s novel approach to anti-cancer therapy," said Dr. Stephen A. Hill, President and Chief Executive Officer. "The ACT(SM) platform underscores ArQule`s oncology portfolio which presently consists of a Phase 1 clinical candidate (ARQ 501) and several discovery programs."
Dr. Chiang J. Li, inventor of the ACT(SM) platform and senior author of the study, added, "My colleagues and I are honored by this peer recognition of our science. We are working to improve the way cancer patients are treated."
The November/December 2003 issue of Cell Cycle acknowledges the most outstanding cell cycle research of the past year with its selection of the top ten papers, chosen from among 40 papers published in all journals between 2002 and mid-2003. The papers were nominated and selected by members of the Cell Cycle Editorial Board who used the following criteria: will the paper affect future basic research or research in therapy or does it describe a new technology?
ArQule, Inc. is a biotechnology company engaged in the research and development of novel small-molecule drugs for the treatment of cancer and inflammation. The Company is applying its innovative Activated Checkpoint Therapy(SM) (ACT(SM)) platform and its small-molecule chemistry expertise to produce next-generation drugs that are aimed at improving the treatment of cancer patients. ACT(SM) platform compounds are intended to selectively kill cancer cells and spare normal cells by restoring and activating cellular checkpoints that are defective in cancer.
ArQule`s leading programs are ARQ 501 for solid cancers, which entered Phase 1 trials in September 2003, and ARQ 101, an OCE(TM) compound targeting p38 MAP Kinase for rheumatoid arthritis, which entered preclinical testing (GLP-toxicity studies) in November.
For more information about Cell Cycle and the current issue, please visit: www.landesbioscience.com/journals/cc/.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in the forward-looking statements or historical performance due to numerous risks and uncertainties that exist in ArQule`s operations, development efforts and the business environment, including without limitation: the ability to integrate successfully ArQule`s biology experience and the ACT(SM) platform with its small-molecule chemistry expertise; the ability to improve the treatment of cancer patients; the ACT(SM) platform may not improve efficacy or reduce toxicity and compounds resulting from the platform may not operate as intended; and, the risks and uncertainties described in ArQule`s Form 10-K filed with the Securities and Exchange Commission on March 31, 2003 and its Form S-3 filed with the Commission on October 8, 2003. The forward-looking statements contained herein represent the judgment of ArQule as of the date of this report. ArQule disclaims any intent or obligation to update any forward-looking statement except to the extent required by law.
SOURCE ArQule, Inc. -0- 11/20/2003 /CONTACT: Stephen A. Hill, CEO, or Jean M. Devine, Director of IR, both of ArQule, Inc., +1-781-994-0300/ /Web site: http://www.arqule.com/ (ARQL)
ArQule Reaches Milestones in Agreement With Pfizer And Revises Financial Guidance For 2003
Friday December 19, 7:00 am ET
WOBURN, Mass., Dec. 19 /PRNewswire-FirstCall/ -- As a consequence of achieving certain 2003 goals for its collaboration with Pfizer Inc., ArQule, Inc. (Nasdaq: ARQL - News) today announced an increase in its expected revenues for fiscal year 2003. Some payments, which had been anticipated in January 2004, will now be paid in December 2003. As a result, ArQule is updating financial guidance for the year ended December 31, 2003. The Company expects to release its final results for 2003 and provide financial guidance for 2004 in mid- February 2004.
ADVERTISEMENT
"I am pleased with ArQule`s success in meeting Pfizer goals and appreciate the hard work of our employees who have continued to excel in this collaboration," said Dr. Stephen A. Hill, ArQule`s President and CEO. "Consistent with prior communications about ArQule`s strategy and business model, we intend to prioritize management of cash flow to provide optimal support for our internal oncology programs. It should be noted that these early payments from Pfizer will not be included in our 2004 expectations. Moreover, following the successful completion of our three-year collaboration with Bayer, we do not anticipate any revenues from Bayer after 2003. As noted in the past, our revenue is likely to vary from quarter to quarter."
ArQule now expects 2003 revenues to range between $63 and $65 million. This increase from prior guidance of $58 to $60 million reflects revenues from meeting certain goals in the Pfizer collaboration. The achievement of ArQule`s 2003 collaboration goals triggers a $3 million equity investment from Pfizer. This marks the final of three planned investments in ArQule stock, for a total of $18 million, made by Pfizer since December 2001.
Updating the rest of its guidance for 2003, ArQule now expects: the total cost of revenue to range between $36 and $37 million; total research and development expense to range between $19 and $20 million; marketing, general and administrative expense to range between $9 and $10 million; and net investment income to range between $500,000 and $600,000. ArQule now expects its net loss for 2003 to range between $29 and $31 million, a reduction from previous guidance of $37 to $39 million. This figure includes the impact of the in-process research and development charge of approximately $30 million related to the close of the Cyclis acquisition. ArQule now expects its net use of cash to range between $11 and $13 million, a reduction from previous guidance of $22 to $24 million. This includes payment of substantially all of Cyclis` liabilities of approximately $5 million and the cash portion of the purchase price and closing-related costs of $7 million.
ArQule, Inc. is a biotechnology company engaged in research and development of next-generation small-molecule cancer therapeutics based on its innovative Activated Checkpoint Therapy(SM) (ACT(SM)) platform. ACT(SM) compounds are intended to improve the way cancer patients are treated because they selectively kill cancer cells and spare normal cells by restoring and activating cellular checkpoints that are defective in cancer. The Company`s lead programs are ARQ 501 for solid cancers, presently in Phase 1 clinical trials, and ARQ 101, an optimized small-molecule compound targeting p38 MAP Kinase for rheumatoid arthritis, presently in preclinical (GLP-tox) studies. In addition to advancing its own programs, ArQule continues to advance the drug discovery efforts of pharmaceutical collaborators by providing high- quality library design and compound production.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in the forward-looking statements or historical performance due to numerous risks and uncertainties that exist in ArQule`s operations, development efforts and the business environment, including without limitation: the ability to integrate successfully ArQule`s biology experience and the ACT(SM) platform with its small-molecule chemistry expertise; the ability to improve the treatment of cancer patients; the ACT(SM) platform may not improve efficacy or reduce toxicity and compounds resulting from the platform may not operate as intended; payments may not be received on a timely basis resulting in inaccuracies of the financial projections contained herein; and, the risks and uncertainties described in ArQule`s Form 10-K filed with the Securities and Exchange Commission on March 31, 2003, its Form S-3 filed with the Commission on October 8, 2003 and its Form 10-Q filed with the Commission on November 12, 2003. The forward-looking statements contained herein represent the judgment of ArQule as of the date of this report. ArQule disclaims any intent or obligation to update any forward- looking statement except to the extent required by law.
--------------------------------------------------------------------------------
Source: ArQule, Inc.
Friday December 19, 7:00 am ET
WOBURN, Mass., Dec. 19 /PRNewswire-FirstCall/ -- As a consequence of achieving certain 2003 goals for its collaboration with Pfizer Inc., ArQule, Inc. (Nasdaq: ARQL - News) today announced an increase in its expected revenues for fiscal year 2003. Some payments, which had been anticipated in January 2004, will now be paid in December 2003. As a result, ArQule is updating financial guidance for the year ended December 31, 2003. The Company expects to release its final results for 2003 and provide financial guidance for 2004 in mid- February 2004.
ADVERTISEMENT
"I am pleased with ArQule`s success in meeting Pfizer goals and appreciate the hard work of our employees who have continued to excel in this collaboration," said Dr. Stephen A. Hill, ArQule`s President and CEO. "Consistent with prior communications about ArQule`s strategy and business model, we intend to prioritize management of cash flow to provide optimal support for our internal oncology programs. It should be noted that these early payments from Pfizer will not be included in our 2004 expectations. Moreover, following the successful completion of our three-year collaboration with Bayer, we do not anticipate any revenues from Bayer after 2003. As noted in the past, our revenue is likely to vary from quarter to quarter."
ArQule now expects 2003 revenues to range between $63 and $65 million. This increase from prior guidance of $58 to $60 million reflects revenues from meeting certain goals in the Pfizer collaboration. The achievement of ArQule`s 2003 collaboration goals triggers a $3 million equity investment from Pfizer. This marks the final of three planned investments in ArQule stock, for a total of $18 million, made by Pfizer since December 2001.
Updating the rest of its guidance for 2003, ArQule now expects: the total cost of revenue to range between $36 and $37 million; total research and development expense to range between $19 and $20 million; marketing, general and administrative expense to range between $9 and $10 million; and net investment income to range between $500,000 and $600,000. ArQule now expects its net loss for 2003 to range between $29 and $31 million, a reduction from previous guidance of $37 to $39 million. This figure includes the impact of the in-process research and development charge of approximately $30 million related to the close of the Cyclis acquisition. ArQule now expects its net use of cash to range between $11 and $13 million, a reduction from previous guidance of $22 to $24 million. This includes payment of substantially all of Cyclis` liabilities of approximately $5 million and the cash portion of the purchase price and closing-related costs of $7 million.
ArQule, Inc. is a biotechnology company engaged in research and development of next-generation small-molecule cancer therapeutics based on its innovative Activated Checkpoint Therapy(SM) (ACT(SM)) platform. ACT(SM) compounds are intended to improve the way cancer patients are treated because they selectively kill cancer cells and spare normal cells by restoring and activating cellular checkpoints that are defective in cancer. The Company`s lead programs are ARQ 501 for solid cancers, presently in Phase 1 clinical trials, and ARQ 101, an optimized small-molecule compound targeting p38 MAP Kinase for rheumatoid arthritis, presently in preclinical (GLP-tox) studies. In addition to advancing its own programs, ArQule continues to advance the drug discovery efforts of pharmaceutical collaborators by providing high- quality library design and compound production.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in the forward-looking statements or historical performance due to numerous risks and uncertainties that exist in ArQule`s operations, development efforts and the business environment, including without limitation: the ability to integrate successfully ArQule`s biology experience and the ACT(SM) platform with its small-molecule chemistry expertise; the ability to improve the treatment of cancer patients; the ACT(SM) platform may not improve efficacy or reduce toxicity and compounds resulting from the platform may not operate as intended; payments may not be received on a timely basis resulting in inaccuracies of the financial projections contained herein; and, the risks and uncertainties described in ArQule`s Form 10-K filed with the Securities and Exchange Commission on March 31, 2003, its Form S-3 filed with the Commission on October 8, 2003 and its Form 10-Q filed with the Commission on November 12, 2003. The forward-looking statements contained herein represent the judgment of ArQule as of the date of this report. ArQule disclaims any intent or obligation to update any forward- looking statement except to the extent required by law.
--------------------------------------------------------------------------------
Source: ArQule, Inc.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,17 | |
| -0,73 | |
| -0,48 | |
| 0,00 | |
| +20,00 | |
| 0,00 | |
| +0,49 | |
| 0,00 | |
| +2,80 | |
| 0,00 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 228 | ||
| 174 | ||
| 89 | ||
| 81 | ||
| 55 | ||
| 51 | ||
| 43 | ||
| 41 | ||
| 34 | ||
| 30 |
